

**Ofrecer respuestas para la EPOC (Enfermedad Pulmonar Obstructiva Crónica): Estrategias prácticas para mejorar el diagnóstico precoz y el tratamiento centrado en el paciente en la atención primaria:
Tratamiento farmacológico de la EPOC: Tweetorial #3**

Referencias

Tweet 4

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 5

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 6

Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). *Eur Respir J.* 2015;45:969-979. doi:10.1183/09031936.00136014

Calverley PMA, de la Hoz A, Xue W, Ferguson GT, Miravitles M. COPD maintenance therapy with tiotropium/olodaterol compared with tiotropium: an analysis in the absence of additional ICS therapy. *COPD.* 2020;17:477-484. doi:10.1080/15412555.2020.1813269

Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. *Lancet Respir Med.* 2018;6(5):337-344. doi:10.1016/S2213-2600(18)30102-4

Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. *Int J Chron Obstruct Pulmon Dis.* 2018;13:2147-2156. doi:10.2147/COPD.S169941

Lipari M, et al. Dual- versus mono-bronchodilator therapy in moderate to severe COPD: a meta-analysis. *Ann Pharmacother.* 2020;54(12):1232-1242. doi:10.1177/1060028020932134

Mammen MJ, Pai V, Aaron DS, et al. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. a systematic review and meta-analysis in support of the american thoracic society clinical practice guideline. *Ann Am Thorac Soc.* 2020;17:1133-1143. doi:10.1513/AnnalsATS.201912-915OC

Maltais F, Bjemer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res.* 2019;20:238. doi:10.1186/s12931-019-1193-9

Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. *Respir Res.* 2016;17:73. doi:10.1186/s12931-016-0387-7

Singh D, D'Urzo AD, Chuecos F, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. *Respir Res.* 2017;18:106. doi:10.1186/s12931-017-0583-0

Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med*. 2013;1:199-209. doi:10.1016/S2213-2600(13)70052-3

Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled analysis of the TONADO®/DYNAGITO® trials. *Adv Ther*. 2020;37:4266-4279.

Tweets 8 & 9

National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Updated May 2019. Accessed June 2022.
<https://www.nice.org.uk/guidance/ng115>

Tweet 10

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 11

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 12

IPCRG Desktop Helper. Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). May 2020. Accessed March 2, 2022.
<https://www.ipcrg.org/sites/ipcrg/files/content/attachments/2020-06-02/IPCRG%20DH6%20ICS%20COPD%20Rev%20May20.pdf>

Tweet 13

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med*. 2020;383:35-48. doi:10.1056/NEJMoa1916046

Tweet 14

Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*. 2014;371:1285-1294. doi:10.1056/NEJMoa1407154

Tweet 17

Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. *Ther Adv Respir Dis*. 2019;13:1753466619884532. doi: 10.1177/1753466619884532

Tweet 18

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev*. 2016;2016: Cd006103.
doi:10.1002/14651858.CD006103.pub7

Rigotti NA, Kruse GR, Livingstone-Bank J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. *JAMA*. 2022;327(6):566-577.

Tweet 19

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>